Dissection of the multiple sclerosis associated DR2 haplotype

Journal of Autoimmunity

Volumn 31, Issue 3, 2008, Pages 201-207

  Etzensperger, Ruth ^a   McMahon, Róisín M ^a,b   Jones, E Yvonne ^b   Fugger, Lars ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Epistasis; HLA class II; Multiple sclerosis; Protein crystallography; T cells

Indexed keywords

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENE INTERACTION; HAPLOTYPE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; HAPLOTYPES; HLA-DR2 ANTIGEN; HUMANS; MICE; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 56649092924     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.04.016     Document Type: Article

References (44)

1. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747
2. Compston D.A., Batchelor J.R., and McDonald W.I. B-lymphocyte alloantigens associated with multiple sclerosis. Lancet 2 (1976) 1261-1265
3. Oksenberg J.R., Barcellos L.F., Cree B.A., Baranzini S.E., Bugawan T.L., Khan O., et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 74 (2004) 160-167
4. The International HapMap Consortium. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
5. Miretti M.M., Walsh E.C., Ke X., Delgado M., Griffiths M., Hunt S., et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 76 (2005) 634-646
6. Gregersen J.W., Kranc K.R., Ke X., Svendsen P., Madsen L.S., Thomsen A.R., et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 443 (2006) 574-577
7. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72 (2003) 710-716
8. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15 (2006) 2813-2824
9. Deluca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 104 (2007) 20896-20901
10. Krogsgaard M., Wucherpfennig K.W., Cannella B., Hansen B.E., Svejgaard A., Pyrdol J., et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med 191 (2000) 1395-1412
11. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357 (2007) 851-862
12. Rich C., Link J.M., Zamora A., Jacobsen H., Meza-Romero R., Offner H., et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol 34 (2004) 1251-1261
13. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 (2000) 1167-1175
14. Madsen L.S., Andersson E.C., Jansson L., krogsgaard M., Andersen C.B., Engberg J., et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 23 (1999) 343-347
15. Wucherpfennig K.W., Zhang J., Witek C., Matsui M., Modabber Y., Ota K., et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 152 (1994) 5581-5592
16. Lang H.L.E., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3 (2002) 940-943
17. Ellmerich S., Mycko M., Takacs K., Waldner H., Wahid F.N., Boyton R.J., et al. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 174 (2005) 1938-1946
18. Illes Z., Stern J.N., Reddy J., Waldner H., Mycko M.P., Brosnan C.F., et al. Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proc Natl Acad Sci U S A 101 (2004) 11749-11754
19. Illes Z., Stern J.N., Keskin D.B., Reddy J., Brosnan C.F., Waldner H., et al. Copolymer effects on microglia and T cells in the central nervous system of humanized mice. Eur J Immunol 35 (2005) 3683-3693
20. Kabelitz D., and Janssen O. Antigen-induced death of T-lymphocytes. Front Biosci 2 (1997) d61-d77
21. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81 (1995) 935-946
22. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A., Debatin K.M., Fischer A., et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268 (1995) 1347-1349
23. Phillips P.C. The language of gene interaction. Genetics 149 (1998) 1167-1171
24. Sospedra M., Zhao Y., zur Hausen H., Muraro P.A., Hamashin C., de Villiers E.M., et al. Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog 1 (2005) e41
25. Jones E.Y., Fugger L., Strominger J.L., and Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 6 (2006) 271-282
26. Matsuki K., Grumet F.C., Lin X., Gelb M., Guilleminault C., Dement W., et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 339 (1992) 1052
27. Mignot E., Lin L., Rogers W., Honda Y., Qiu X., Lin X., et al. Complex HLA-DR and DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68 (2001) 686-699
28. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364 (1993) 33-39
29. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368 (1994) 215-221
30. Siebold C., Hansen B.E., Wyer J.R., Harlos K., Esnouf R.E., Svejgaard A., et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci U S A 101 (2004) 1999-2004
31. Anderton S.M., and Wraith D.C. Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol 2 (2002) 487-498
32. Anderton S.M., Radu C.G., Lowrey P.A., Ward E.S., and Wraith D.C. Negative selection during the peripheral immune response to antigen. J Exp Med 193 (2000) 1-12
33. Carrasco-Marin E., Shimizu J., Kanagawa O., and Unanue E.R. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. J Immunol 156 (1996) 450-458
34. Buljevac D., Flach H.Z., Hop W.C., Hijdra D., Laman J.D., Savelkoul H.F., et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125 (2002) 952-960
35. Oldstone M.B.A. Molecular mimicry and autoimmune disease. Cell 50 (1987) 819-820
36. Li Y., Li H., Martin R., and Mariuzza R.A. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J Mol Biol 304 (2000) 177-188
37. Ghosh P., Amaya M., Mellins E., and Wiley D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378 (1995) 457-462
38. Vogt A.B., Kropshofer H., Kalbacher H., Kalbus M., Rammensee H.G., Coligan J.E., et al. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 153 (1994) 1665-1673
39. Wucherpfennig K.W., Sette A., Southwood S., Oseroff C., Matsui M., Strominger J.L., et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 179 (1994) 279-290
40. Hahn M., Nicholson M.J., Pyrdol J., and Wucherpfennig K.W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol 6 (2005) 490-496
41. Li Y., Huang Y., Lue J., Quandt J.A., Martin R., and Mariuzza R.A. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 24 (2005) 2968-2979
42. Hennecke J., Carfi A., and Wiley D.C. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J 19 (2000) 5611-5624
43. Rudolph M.G., Stanfield R.L., and Wilson I.A. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24 (2006) 419-466
44. Maynard J., Petersson K., Wilson D.H., Adams E.J., Blondelle S.E., Boulanger M.J., et al. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity 22 (2005) 81-92